Evaluation of Clinical Findings and Treatment Outcomes of Patients Diagnosed with Primary Membranous Nephropathy: A Single Center Experience

Gamze Coşkun Kılınç; Ömer Faruk Akçay; Ebru Gök Oğuz; Mehmet Deniz Aylı

Makale detayları

Evaluation of Clinical Findings and Treatment Outcomes of Patients Diagnosed with Primary Membranous Nephropathy: A Single Center Experience

Yazarlar:

Gamze Coşkun Kılınç | Ömer Faruk Akçay | Ebru Gök Oğuz | Mehmet Deniz Aylı

Yayıncı:

Akdeniz University

Ana Başlıklar:

Nefroloji

Dergi:

Akdeniz Tıp Dergisi Vol.11 Issue 3, pp.419-427

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357307

pISSN:

2687-2781

Anahtar kelimeler:

Özet:

 Objective: Membranous nephropathy MN is the most common cause of nephrotic syndrome in non-diabetic white adults. The primary aim of our study is to compare the demographic and clinical characteristics, treatment outcomes, and the occurrence of remission in patients with primary MN. Materials and Methods: Our study included 35 patients diagnosed with primary MN between January 2012 and January 2021. Based on risk classification, patients were distributed across low, moderate, high, and very high-risk groups. All patients were treated under Kidney Disease: Improving Global Outcomes KDIGO guidelines. Results: The mean age of our patients was 55.910.8 years, and 71.4 were male. At diagnosis, almost all patients 97.1 had nephrotic-level proteinuria. In the risk classification of the patients with MN, 13 37.1 patients were low risk, 11 31.4 patients were moderate risk, 8 22.9 patients were high risk, and 3 8.6 patients were in the very high-risk group. The overall remission rate at the end of the first year was 68.6. The mean age of patients who achieved remission was 52.810.5, while the mean age of patients who did not achieve remission was 62.98.4 p0.008. The most commonly used immunosuppressive IS agent that combined with steroids was cyclophosphamide 65.7, followed by calcineurin inhibitors 45.7. Conclusion: High overall remission rates were observed at the end of the first year of MN treatment. IS treatment applied to MN patients may contribute to early remission.

 Objective: Membranous nephropathy MN is the most common cause of nephrotic syndrome in non-diabetic white adults. The primary aim of our study is to compare the demographic and clinical characteristics, treatment outcomes, and the occurrence of remission in patients with primary MN. Materials and Methods: Our study included 35 patients diagnosed with primary MN between January 2012 and January 2021. Based on risk classification, patients were distributed across low, moderate, high, and very high-risk groups. All patients were treated under Kidney Disease: Improving Global Outcomes KDIGO guidelines. Results: The mean age of our patients was 55.910.8 years, and 71.4 were male. At diagnosis, almost all patients 97.1 had nephrotic-level proteinuria. In the risk classification of the patients with MN, 13 37.1 patients were low risk, 11 31.4 patients were moderate risk, 8 22.9 patients were high risk, and 3 8.6 patients were in the very high-risk group. The overall remission rate at the end of the first year was 68.6. The mean age of patients who achieved remission was 52.810.5, while the mean age of patients who did not achieve remission was 62.98.4 p0.008. The most commonly used immunosuppressive IS agent that combined with steroids was cyclophosphamide 65.7, followed by calcineurin inhibitors 45.7. Conclusion: High overall remission rates were observed at the end of the first year of MN treatment. IS treatment applied to MN patients may contribute to early remission.

 Objective: Membranous nephropathy MN is the most common cause of nephrotic syndrome in non-diabetic white adults. The primary aim of our study is to compare the demographic and clinical characteristics, treatment outcomes, and the occurrence of remission in patients with primary MN. Materials and Methods: Our study included 35 patients diagnosed with primary MN between January 2012 and January 2021. Based on risk classification, patients were distributed across low, moderate, high, and very high-risk groups. All patients were treated under Kidney Disease: Improving Global Outcomes KDIGO guidelines. Results: The mean age of our patients was 55.910.8 years, and 71.4 were male. At diagnosis, almost all patients 97.1 had nephrotic-level proteinuria. In the risk classification of the patients with MN, 13 37.1 patients were low risk, 11 31.4 patients were moderate risk, 8 22.9 patients were high risk, and 3 8.6 patients were in the very high-risk group. The overall remission rate at the end of the first year was 68.6. The mean age of patients who achieved remission was 52.810.5, while the mean age of patients who did not achieve remission was 62.98.4 p0.008. The most commonly used immunosuppressive IS agent that combined with steroids was cyclophosphamide 65.7, followed by calcineurin inhibitors 45.7. Conclusion: High overall remission rates were observed at the end of the first year of MN treatment. IS treatment applied to MN patients may contribute to early remission.

 Amaç: Membranöz nefropati MN, diyabetik olmayan beyaz yetişkinlerde nefrotik sendromun en yaygın nedenidir. Çalışmamızın temel amacı, primer MN tanısı alan hastaların demografik ve klinik özelliklerini, tedavi sonuçlarını ve remisyon oluşumunu karşılaştırmaktır. Gereç ve Yöntemler: Çalışmamıza, Ocak 2012 ile Ocak 2021 arasında primer MN tanısı alan 35 hasta dahil edilmiştir. Risk sınıflandırmasına dayalı olarak hastalar düşük, orta, yüksek ve çok yüksek risk gruplarına dağıtılmıştır. Tüm hastalar, Böbrek Hastalığı: Sonuçların İyileştirilmesi KDIGO kılavuzları altında tedavi edilmiştir. Bulgular: Hastalarımızın ortalama yaşı 55.910.8 yıl olup, çoğunluğu 71.4 erkekti. Tanı anında hastaların neredeyse tamamında 97.1 nefrotik seviyede proteinüri mevcuttu. MN için yapılan risk sınıflandırmasında, 13 37.1 hasta düşük risk grubunda, 11 31.4 hasta orta risk grubunda, 8 22.9 hasta yüksek risk grubunda ve 3 8.6 hasta çok yüksek risk grubunda yer aldı. İlk yıl sonunda genel remisyon oranı 68.6 idi. Remisyon elde eden hastaların ortalama yaşı 52.810.5 iken, remisyon elde edemeyen hastaların ortalama yaşı 62.98.4 idi p0.008. Steroidlerle birlikte en yaygın kullanılan immünosupresif IS ajan, siklofosfamid 65.7 olup, bunu kalsinörin inhibitörleri 45.7 takip etti. Sonuç: Tek merkezli çalışmamızda, literatürle tutarlı olarak MN tedavisinin ilk yılı sonunda yüksek genel remisyon oranları gözlemlenmiştir. MN hastalarına uygulanan IS tedavi, erken remisyona katkıda bulunabilir.

Makale detayları

Evaluation of Clinical Findings and Treatment Outcomes of Patients Diagnosed with Primary Membranous Nephropathy: A Single Center Experience

Yazarlar:

Gamze Coşkun Kılınç | Ömer Faruk Akçay | Ebru Gök Oğuz | Mehmet Deniz Aylı

Yayıncı:

Akdeniz University

Ana Başlıklar:

Nefroloji

Dergi:

Akdeniz Tıp Dergisi Vol.11 Issue 3, pp.419-427

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357307

pISSN:

2687-2781

Membranous nephropathy

remission

immunosuppressive treatment

proteinuriaMembranöz nefropati

remisyon

immünosupresif tedavi

proteinüri

Sayı

Makale detayları

Yazarlar: Gamze Coşkun Kılınç | Ömer Faruk Akçay | Ebru Gök Oğuz | Mehmet Deniz Aylı

Yayıncı: Akdeniz University

Ana Başlıklar: Nefroloji

Dergi: Akdeniz Tıp Dergisi Vol.11 Issue 3, pp.419-427

Belge Tipi: Makale

Yayın Tarihi: 9/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001357307

pISSN: 2687-2781

Sayı

Yazarlar:

Gamze Coşkun Kılınç | Ömer Faruk Akçay | Ebru Gök Oğuz | Mehmet Deniz Aylı

Yayıncı:

Akdeniz University

Ana Başlıklar:

Nefroloji

Dergi:

Akdeniz Tıp Dergisi Vol.11 Issue 3, pp.419-427

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357307

pISSN:

2687-2781